HCW Biologics Inc. 8-K

What Happened HCW Biologics Inc. filed an 8‑K on February 13, 2026, announcing an exclusive worldwide license agreement with WY Biotech Co., Ltd. The agreement grants WY Biotech development and commercialization rights for certain in vivo applications of HCW Biologics’ proprietary molecule HCW11‑006. The deal also includes, for additional consideration, an option for WY Biotech to license exclusive Greater China clinical development and commercialization rights for HCW9302, HCW Biologics’ clinical‑stage molecule being evaluated for an autoimmune disorder. The related press release is furnished as Exhibit 99.1 to the filing.

Key Details

• Date filed: February 13, 2026.
• Counterparty: WY Biotech Co., Ltd., a China‑based company focused on early‑stage recombinant protein and gene/cell therapy development.
• Scope: Exclusive worldwide license for certain in vivo uses of HCW11‑006; option to license exclusive Greater China rights for HCW9302 (clinical‑stage for an autoimmune disorder).
• Financial terms: Not disclosed in the 8‑K; press release provided as Exhibit 99.1.

Why It Matters This agreement expands HCW Biologics’ pathway for development and potential commercialization by partnering with a China‑based developer for global (HCW11‑006) and regional (HCW9302 Greater China option) opportunities. For investors, the deal could accelerate development timelines or market access for these molecules, but the 8‑K does not disclose financial terms, milestones, or royalties that would determine any near‑term revenue or cash impact.